Standard BioTools Announces Sale of Mass Cytometry Business to Multiplex Bio

What Happened
Standard BioTools Inc. (LAB) filed an 8-K on July 29, 2026 disclosing that it entered into a Share and Asset Purchase Agreement dated July 28, 2026 under which Multiplex Bio Inc. will acquire the Company’s mass cytometry business. The Purchase Agreement is attached as Exhibit 2.1 to the filing, with certain non-material and confidential portions omitted.

Key Details

• Agreement date: July 28, 2026; 8-K filed July 29, 2026.
• Buyer: Multiplex Bio Inc.; Seller: Standard BioTools Inc.; subject: the Company’s mass cytometry business.
• Exhibit 2.1 (Share and Asset Purchase Agreement) is included, with portions omitted pursuant to Item 601(b)(10)(iv) of Regulation S‑K and certain schedules/attachments omitted under Item 601(a)(5). The company will provide omitted schedules to the SEC upon request.
• The filing states that the contractual representations, warranties and covenants in the Purchase Agreement were made for the parties’ benefit and may be qualified by confidential disclosures and contractual materiality standards, and thus should not be taken as definitive statements of the company’s factual condition.

Why It Matters
This 8-K announces a material transaction — the divestiture of Standard BioTools’ mass cytometry business — which could affect the company’s future revenue mix, product portfolio and operations. The filing does not disclose purchase price or detailed financial terms; investors should watch for future filings (e.g., amendments, pro forma financials or press releases) for the transaction’s financial impact and closing conditions. Also note the company’s caution that the Purchase Agreement’s reps and warranties are contractual and may not reflect the actual state of facts for investors.